AACR 2020: PD-L1 single-resistant Tecentriq combined carplatinand and etoposide to improve SCLC survival rate for small cell lung cancer

The latest data from the IMpower133 study, presented at the 2020 American Cancer Research Association (AACR) online meeting, assessed the efficacy and safety of Roche's PD-L1 monoantitic Teriq (atezolizumab) combination of caropherinandandandine and endocoside to treat patients with a wide range of small cell lung cancer (SCLC)"Adding atezolizumab to cabeandandandanda can provide a near-improvement in the overall survival rate of patients with a wide range of SCLCs," said Leora Horn, M.D., at Vanderbilt University in Nashville, TennesseeThe latest results from IMpower133 further support the program's use of untreated, widespread small cell lung cancer???the findings of theIMpower133 show that adding atezolizumab to cappelin and optopoine alone can achieve overall survival and progression-free survival rates statistically and clinically compared to the use of calplatin and etoposide alonesignificant improvementafter 22.9 months of median follow-up, the average total lifetime of 201 patients randomly assigned to atezolizumab combined with carnitine and endoside was 12.3 months, while the median total survival of 202 patients who were randomly treated with carpedandi and endopolycoside was 10.3 months